CN1853615A - Tablet containing brufen and producing process thereof - Google Patents
Tablet containing brufen and producing process thereof Download PDFInfo
- Publication number
- CN1853615A CN1853615A CNA2006100550134A CN200610055013A CN1853615A CN 1853615 A CN1853615 A CN 1853615A CN A2006100550134 A CNA2006100550134 A CN A2006100550134A CN 200610055013 A CN200610055013 A CN 200610055013A CN 1853615 A CN1853615 A CN 1853615A
- Authority
- CN
- China
- Prior art keywords
- brufen
- particle
- grams
- microns
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The ibuprofen-containing tablet is produced by the compression molding of ibuprofen powder or ibuprofen-containing granules wherein the particle diameter of >=70 mass% of the particle is 75-1,000 microns. The method for the production of the ibuprofen-containing tablet is characterized in the compression molding of ibuprofen powder or ibuprofen-containing granules after adjusting the particle diameter of >=70 mass% of the particle to be 75-1,000 microns.
Description
The application is the divisional application of Chinese patent application 200410085610.2
The applying date: on October 9th, 2004
Application number: 200410085610.2
Denomination of invention: tablet and its manufacturing method containing brufen
Technical field
The present invention relates to a kind of tablet containing brufen (ibuprofen) more particularly to a kind of tablet manufacturing methods containing brufen, can inhibit to bond in compression forming, and may insure content uniformity.
Background technique
Brufen is a kind of drug for being used in analgesic agent extensively, is widely used in a manner of oral administration, non-oral administration.
However, when manufacturing the modulated tablet equipped with brufen, it is known that in compression forming, a part of medicament constituent is adhered to the tabletting obstacle (bonding) in pestle front end frequent occurrence.Since the tablet for occurring to bond in this way lacks a part, not only appearance is bad, and influences content uniformity, can become the significant drawback for being related to product.
Summary of the invention
Such bonding in order to prevent, it is general used by method have the method for increasing lubricant, increase excipient to reduce the ratio of brufen in tabletting powder and the methods of tabletting, but the effect of these methods and insufficient.
Be the tabletting method (Japanese documentation 1) of 1 ~ 100 micron of crystalline powder, add silica-based and tabletting method (patent document 2) in the grease substrate for being surrounded by physiological activity object inside, contain the method (patent document 3) that average grain diameter made of drug core material is 300 microns of putting property of Xu particles progress compression formings below using hydrophobic organic compound-water soluble polymer mixing coating film in addition, there is report to disclose allotment average grain diameter.
But these methods it is effective it is insufficient, processing procedure thickens that cost is caused to improve.
[patent document 1] Japanese Laid-Open Patent Publication 10-59842
[patent document 2] Japanese Laid-Open Patent Publication 11-35487
[patent document 3] special open 2000-198747
It thus requires to provide a kind of manufacturing method containing brufen tablet more cheaper than known techniques, easy.
Inventor etc. finds out that the reason of preparation containing brufen is bonded in compression forming is because containing thinner particle in brufen original powder end.Further, it was found that tabletting is promoted when these are excluded significantly, when tabletting, can not be bonded.Additionally, it was found that by excluding the big particle in original powder end, it can be ensured that determination of ibuprofen uniformity in acquired preparation and complete the present invention.
That is the tablet of the invention for containing brufen be using the particle diameter of 70 mass % or more be 75 microns ~ 1000 microns original powder end or brufen contain particle as tabletting powder, progress compression forming and obtain.
In addition, the present invention provides a kind of tablet manufacturing method containing brufen, it is characterized in that, brufen original powder end or the particle containing brufen are subjected to compression forming to it after the particle diameter for being adjusted to 70 mass % or more is 75 microns ~ 1000 microns.
According to the present invention, more than step is simple and can prevent the bonding when manufacturing the tablet containing brufen.
Embodiment
When manufacturing the tablet of the invention containing brufen, adjusts and be important as the brufen original powder end of raw material and the particle containing brufen.Brufen original powder end and particle (hereinafter referred to as " brufen original powder end etc. ") partial size containing brufen must be adjusted to the particle diameter of all 70 mass %, more preferably 90 mass % or more in 75 microns ~ 1000 micron ranges.
It may be thus possible, for example, to by compression forming raw material is used as without the brufen original powder end etc. by 200 sieve meshes by 16 sieve meshes.
In the brufen original powder end of raw material, the white crystalline powder that brufen amount is 98.5% or more is commercially available to have various partial sizes.
It on the other hand, is to add excipient (mainly adhesive) etc. in above-mentioned brufen original powder end in about 50 microns of particles below of average grain diameter and so that its partial size is become larger by granulation etc. containing the particle of brufen.It in the ibuprofen granule, is preferred with determination of ibuprofen the higher person, is greater than 50 mass % and is preferred.The concentration of the particle containing brufen is improved as far as possible, and the pestle face for reducing tabletting whereby the probability of brufen occurs and less easily bonds.In addition, because the determination of ibuprofen in particle is possible to change when adjusting the grain diameter containing brufen using sieve determination of ibuprofen must be measured after adjusting partial size sometimes, make corrections its content.
In the present invention, preferable brufen original powder end etc. is adjusted to all 70 mass % or more, more preferably 90 mass %, and the above are the particles in 106 microns ~ 710 micron ranges, and particularly good is 70% or more all quality, the above are the particles in 150 microns ~ 500 micron ranges by more preferably 90 mass %.
Such brufen can not obtained by the particle of 100 sieve meshes by the particle of 140 sieve meshes, by 30 sieve meshes from each by 22 sieve meshes.In addition, used sieve when partial size adjusts in this specification, there is no particular limitation, for instance, it is not necessary to say the brufen using grader also available purpose partial size.
Tablet containing brufen of the invention, be form in adjustment as described above, as adding excipient appropriate among brufen original powder end of raw material etc., being sufficiently mixed after, can be according to usual way tabletting.It can be by any in having adjusted the last particle containing brufen of brufen original powder of the particle within the scope of specified particle size or deployed in mixture made of these ingredients with adequate rate, excipient appropriate is more added, which is made.
Brufen original powder end etc. is preferred with brufen in tablet with the content of 10 ~ 50 mass % degree.When content is below 10%, tablet particle is too big, in addition, even if controlling partial size according to the present invention, when tabletting can also bond when determination of ibuprofen is greater than 50 weight % in tabletting powder.
In addition, used excipient when preparation, used raw material when usually manufacture solid bodies can be used, for example, have lactose, starch, cornstarch, α starch, part α starch, avicel cellulose, low degree of substitution hydroxypropyl cellulose, hydroxypropyl cellulose, castor sugar, glycitols, light silicon anhydride, calcium silicates etc..One kind or two kinds or more can be used in these excipient.
, can be according to needs when manufacturing tablet containing brufen, then add adhesive, disintegrating agent, lubricant etc., these examples are adducible as follows.
Adducible adhesive has such as gelatin, gum arabic, methylcellulose, carboxyl methylcellulose, carboxymethyl cellulose sodium salt, hydroxypropyl methylcellulose, polyethylene cough up pyridine ketone, pullulan, dextrin, hydroxyl methylcellulose calcium salt, hydroxyl methylcellulose sodium salt, and one of which or two kinds or more can be used.
In addition, the adducible example of disintegrating agent, which has, intersects that hydroxy-methyl cellulose sodium (crosscarboxylmethyl cellulose calcium), insoluble polyvinyl cough up pyridine ketone, the insoluble polyvinyl of crosslinking coughs up pyridine ketone (crosslinked insoluble polyvinyl pyrrolidone), cellulose calcium salt, Sodium carboxymethyl starch, potato starch, cornstarch, alphalysed starch etc., can be used one of or two kinds or more.
In addition, the adducible example of lubricant has talcum, stearic acid, magnesium stearate, sucrose-fatty esters, polyethylene glycol etc., one of which or two kinds or more can be used.
Then, the present invention is described in more detail with embodiment, but the present invention and be not affected by these embodiment any restrictions.
(embodiment 1)
It is added in 24 grams of di(2-ethylhexyl)phosphate hydrocodeines, 60 grams of d1- hydrochloride methyl ephedrines, the different benzene Isopropamide of 6 grams of iodate, 48 grams of Codipects (noscapine), 7.5 grams of chlorphenylamine maleates, 300 grams of ascorbic acid, 24 grams of ammonium nitrates, 75 grams of Caffeine Anhydrous acid anhydrides in powder mixture made of the excipient such as 1408.5 grams of avicel celluloses, light silicon anhydride, lactose, hydroxypropylcelluloses after adding Purified Water, carrying out wet type granulation, it is dry, particle is made.The particle is subjected to choosing grain using COMIL (throwing Lek society system), obtains 1953 grams of particles (A).
On the other hand, choosing grain is carried out using 200 sieve meshes (75 microns of eyelet diameter) and 16 sieve meshes (100 microns of eyelet diameter) sieve to brufen original powder end, it is last (B) obtains the brufen original powder that 450 gram particle diameters are 75 ~ 1000 microns.It is as shown in Figure 1 with the granularity distribution result of laser diffraction mode particle size distribution device investigation original powder last (B).
After 1953 grams of above-mentioned obtained brufen original powders for selecting particle obtained by grain (A) to select grain to obtain with 450 grams last (B) are mixed, 15 grams of talcums and 12 grams of magnesium stearates are added again and are mixed, tabletting is carried out using rotary pelleting machine, the uncoated tablet (uncoated tablet) of 270mg/tb. is made.
(embodiment 2)
Choosing grain is carried out using 140 sieve meshes (106 microns of eyelet diameter) and 22 sieve meshes (710 microns of eyelet diameter) sieve to brufen original powder end, obtains the brufen original powder end that 450 gram particle diameters are 106 ~ 710 microns.
After selecting particle obtained by grain (A) to mix with 450 grams of above-mentioned obtained brufen original powders of choosing grain last (C) 1953 grams of embodiments 1, it more adds 15 grams of talcums and 12 grams of magnesium stearates and mixes, tabletting is carried out using rotary pelleting machine, the uncoated tablet of 270mg/tb. is made.
(embodiment 3)
It is added in 240 grams of Caffeine Anhydrous acid anhydrides in the powder mixture that the excipient such as 546 grams of avicel celluloses, low degree of substitution hydroxypropyl cellulose, lactose, hydroxypropylcelluloses form after adding Purified Water, carrying out wet type granulation, it is dry, particle is made.The particle is subjected to choosing grain using COMIL (throwing Lek society system), obtains 786 grams of particles (D).
On the other hand, choosing grain is carried out using 100 sieve meshes (150 microns of eyelet diameter) and 30 sieve meshes (500 microns of eyelet diameter) sieve to brufen original powder end, it is last (E) obtains the brufen original powder that 450 gram particle diameters are 150 ~ 500 microns.
After 786 grams of above-mentioned obtained brufen original powders for selecting particle obtained by grain (D) to select grain to obtain with 450 grams last (E) are mixed, 18 grams of talcums and 6 grams of magnesium stearates are added again and are mixed, tabletting is carried out using rotary pelleting machine, the uncoated tablet of 210mg/tb. is made.
(embodiment 4)
The excipient such as 1208.5 grams of avicel celluloses, light silicon anhydride, lactose, hydroxypropylcelluloses are added in 24 grams of di(2-ethylhexyl)phosphate hydrocodeines, 60 grams of d1- hydrochloride methyl ephedrines, the different benzene Isopropamide of 6 grams of iodate, 48 grams of Codipects (noscapine), 7.5 grams of chlorphenylamine maleates, 300 grams of ascorbic acid, 24 grams of ammonium nitrates, 75 grams of Caffeine Anhydrous acid anhydrides, obtain powder mixture.It is dry after adding Purified Water to it, carrying out wet type granulation, particle is made.The particle is subjected to choosing grain (F) using COMIL (throwing Lek society system).
On the other hand, it is added in powder mixture made of the excipient such as 220 grams of crystallization Crystallization celluloses, light silicon anhydride, hydroxypropylcelluloses at 495 grams of brufen original powder ends, it is dry after addition Purified Water, progress wet type granulation, particle is made.Choosing grain (G) is carried out using 100 sieve meshes (150 microns of eyelet diameter) and 30 sieve meshes (500 microns of eyelet diameter) to the particle.
After selecting the obtained particle of grain (F) to select the obtained brufen original particle (G) of grain to mix with 650 grams for 1753 grams, it adds 15 grams of talcums and 12 grams of magnesium stearates and mixes, tabletting is carried out using rotary pelleting machine, the uncoated tablet of 270mg/tb. is made.
(comparative example 1)
It is last (H) to prepare 450 grams of brufen original powders not by screening grain.
After the particle of grain (A) will be selected to mix obtained by 1953 grams of embodiments 1 with 450 grams of brufen original powders last (H), 15 grams of talcums and 12 grams of magnesium stearates are added again and are mixed, tabletting is carried out using rotary pelleting machine, the uncoated tablet of 270mg/tb. is made.
(comparative example 2)
The excipient such as 1408.5 grams of avicel celluloses, light silicon anhydride, lactose, hydroxypropylcelluloses are added in 450 grams of brufens, 24 grams of di(2-ethylhexyl)phosphate hydrocodeines, 60 grams of d1- hydrochloride methyl ephedrines, the different benzene Isopropamide of 6 grams of iodate, 48 grams of Codipects (noscapine), 7.5 grams of chlorphenylamine maleates, 300 grams of ascorbic acid, 24 grams of ammonium nitrates, 75 grams of Caffeine Anhydrous acid anhydrides, obtain powder mixture.It is dry after adding Purified Water to it, carrying out wet type granulation, particle is made.The particle is subjected to choosing grain (I) using COMIL (throwing Lek society system).
15 grams of talcums of addition and 12 grams of magnesium stearates in the obtained particle of grain (I) are selected at 2403 grams and are mixed, and tabletting is carried out using rotary pelleting machine to this, the uncoated tablet of 270mg/tb. is made.
(test example)
Investigate the bonding of embodiment 1 ~ 4, comparative example 1 and 2 when manufacturing uncoated tablet.For the tabletting for manufacturing uncoated tablet, 2 groups of mortar pestles of rotary pelleting machine device are all within, is 30rpm progress with the rotation number of turntable, observes pestle after tabletting 90 minutes and bond situation, the results are shown in Table 1.
(test result)
[table 1]
| Uncoated tablet | Embodiment | Comparative example |
| 1 2 3 4 | 1 2 | |
| Evaluation | ± - - - | + ++ |
Evaluation criteria
: absolutely not bond
±: almost without bonding
+: there is bonding
++: bonding is serious
From the above results, being clear how that relative to embodiment, almost without bonding, comparative example then bonds.
According to the present invention, only increasing easy steps can prevent from bonding, and the uniform tablet of available determination of ibuprofen.
Therefore, the present invention can be advantageously employed in the tablet containing brufen.
[brief description of drawings]
Fig. 1 shows the figure of the granularity distribution result using brufen original powder last (B) obtained by laser diffraction mode particle size distribution device investigation embodiment.
Claims (8)
1. a kind of tablet containing brufen, it is characterized in that, brufen (ibuprofen) original powder end that the particle using 70 mass % or more is 75 microns ~ 1000 microns or the particle for containing brufen are obtained as tabletting powder by compression forming.
2. a kind of tablet containing brufen, it is characterized in that, brufen (ibuprofen) original powder end that the particle using 70 mass % or more is 106 microns ~ 710 microns or the particle for containing brufen are obtained as tabletting powder by compression forming.
3. a kind of tablet containing brufen, it is characterized in that, brufen (ibuprofen) original powder end that the particle using 70 mass % or more is 150 microns ~ 500 microns or the particle for containing brufen are obtained as tabletting powder by compression forming.
4. any one of the tablet as described in claims 1 to 3 containing brufen, wherein determination of ibuprofen is 10 ~ 50 mass %.
5. any one of the tablet as described in Claims 1-4 containing brufen, wherein brufen original powder end and the particle containing brufen are used in mixed way.
6. a kind of tablet manufacturing method containing brufen, it is characterized in that, brufen original powder end or the particle containing brufen are subjected to compression forming as tabletting powder after the particle for being adjusted to 70 mass % or more is 75 microns ~ 1000 microns.
7. a kind of tablet manufacturing method containing brufen, it is characterized in that, brufen original powder end or the particle containing brufen are subjected to compression forming as tabletting powder after the particle for being adjusted to 70 mass % or more is 106 microns ~ 710 microns.
8. a kind of tablet manufacturing method containing brufen, it is characterized in that, brufen original powder end or the particle containing brufen are subjected to compression forming as tabletting powder after the particle for being adjusted to 70 mass % or more is 150 microns ~ 500 microns.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003-359602 | 2003-10-20 | ||
| JP2003359602A JP4643899B2 (en) | 2003-10-20 | 2003-10-20 | Ibuprofen-containing tablet and method for producing the same |
| JP2003359602 | 2003-10-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100856102A Division CN1636558A (en) | 2003-10-20 | 2004-10-09 | Tablet containing brufen and producing process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1853615A true CN1853615A (en) | 2006-11-01 |
| CN1853615B CN1853615B (en) | 2014-09-24 |
Family
ID=34615777
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610055013.4A Expired - Fee Related CN1853615B (en) | 2003-10-20 | 2004-10-09 | Tablet containing brufen and producing process thereof |
| CNA2004100856102A Pending CN1636558A (en) | 2003-10-20 | 2004-10-09 | Tablet containing brufen and producing process thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100856102A Pending CN1636558A (en) | 2003-10-20 | 2004-10-09 | Tablet containing brufen and producing process thereof |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP4643899B2 (en) |
| KR (1) | KR20050037942A (en) |
| CN (2) | CN1853615B (en) |
| TW (1) | TWI362948B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114982778A (en) * | 2022-06-20 | 2022-09-02 | 戴景文 | Preparation process of compound calcium hypochlorite cake agent for long-acting slow-release disinfection water body and slow-release performance testing method |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4845087B2 (en) * | 2005-05-27 | 2011-12-28 | エスエス製薬株式会社 | Formulation for oral administration |
| JP4864369B2 (en) * | 2005-07-21 | 2012-02-01 | 第一三共ヘルスケア株式会社 | Method for stabilizing thiamines |
| JP5974469B2 (en) * | 2010-12-24 | 2016-08-23 | ライオン株式会社 | Tablet manufacturing method |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1226549B (en) * | 1988-07-12 | 1991-01-24 | Resa Farma | PHARMACEUTICAL COMPOSITIONS WITH ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY FOR ORAL USE, EQUIPPED WITH EXCELLENT PALATABILITY AND FREE FROM IRRITATING EFFECTS ON MUCOSES. |
| IT1276160B1 (en) * | 1995-11-22 | 1997-10-27 | Recordati Chem Pharm | READY-RELEASE ORAL PHARMACEUTICAL COMPOSITIONS FOR EXTEMPORARY SUSPENSIONS |
| US5904937A (en) * | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
-
2003
- 2003-10-20 JP JP2003359602A patent/JP4643899B2/en not_active Expired - Lifetime
-
2004
- 2004-09-16 TW TW093128065A patent/TWI362948B/en not_active IP Right Cessation
- 2004-09-23 KR KR1020040076408A patent/KR20050037942A/en not_active Application Discontinuation
- 2004-10-09 CN CN200610055013.4A patent/CN1853615B/en not_active Expired - Fee Related
- 2004-10-09 CN CNA2004100856102A patent/CN1636558A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114982778A (en) * | 2022-06-20 | 2022-09-02 | 戴景文 | Preparation process of compound calcium hypochlorite cake agent for long-acting slow-release disinfection water body and slow-release performance testing method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1636558A (en) | 2005-07-13 |
| CN1853615B (en) | 2014-09-24 |
| TW200514578A (en) | 2005-05-01 |
| KR20050037942A (en) | 2005-04-25 |
| JP2005120058A (en) | 2005-05-12 |
| TWI362948B (en) | 2012-05-01 |
| JP4643899B2 (en) | 2011-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1154476C (en) | Improved fast disintegrating tablet | |
| CN1081458C (en) | Process for producing active material composition and active material composition | |
| CN1309374C (en) | Improved rapidly disintegratable multiparticulate tablet | |
| CN1186098C (en) | Tablets quickly disintegrated in the oral cavity | |
| CN1211078C (en) | Regulated release preparations | |
| CN1074228A (en) | Microcrystalline celluiose spheronization composition | |
| CN1264298A (en) | Bright white film coatings and film coating compositions therefor | |
| CN1409995A (en) | Synthetic sweetener | |
| CN1536997A (en) | Crystalline composition containing escitalopram | |
| CN1032402C (en) | Granulated medicinal composition and the prepn thereof | |
| CN1845722A (en) | Granular sustained release preparation and production thereof | |
| CN1469880A (en) | Pharmaceutical compositions | |
| CN1178659C (en) | Medicamenet formulation with a controlled release of an active agent | |
| CN1279899C (en) | Process for producing granules containing branched amino acids | |
| CN1582145A (en) | Extended release pharmaceutical composition containing metformin | |
| CN101032489A (en) | Cefprozil dispersible table and the preparing method | |
| CN1853615A (en) | Tablet containing brufen and producing process thereof | |
| CN1446089A (en) | Pharmaceutical composition containing citalopram | |
| CN1709253A (en) | Stable medicinal composition containing pitavastatin | |
| CN1911209A (en) | Quick-disintegration tablets of calcium atovastatine, and its prepn. method | |
| CN1072484C (en) | Tablet and granulate containing sodium 2-mercaptoethanesulfonate | |
| CN1658843A (en) | Tablets having improved tabletting characteristics and process for producing the same | |
| CN1074134A (en) | Granulated medicinal composition and preparation method thereof | |
| CN1203896C (en) | Low sustituted ethylene-lactic cellulose and solid preparation | |
| CN1582927A (en) | Oral disintegrants of nimodipine and their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1093917 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1093917 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140924 Termination date: 20201009 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |